Observational Study of Sifrol® in Patients With Primary Restless Legs Syndrome (RLS)
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1029
- Registration Number
- NCT02248142
Drug Drug Interaction Trial With Strong CYP3A4 Inhibitor (Itraconazole) in CYP2C19 Extensive Metabolizers and Poor Metabolizers
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2024-04-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 25
- Registration Number
- NCT02248259
- Locations
- 🇰🇷
1289.23.8201 Boehringer Ingelheim Investigational Site, Seoul, Korea, Republic of
Effect of BIIL 284 BS on Patients With Chronic Obstructive Pulmonary Disease (COPD)
Phase 2
Completed
- Conditions
- Pulmonary Disease, Chronic Obstructive
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 53
- Registration Number
- NCT02249338
Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type
Phase 2
Completed
- Conditions
- Alzheimer Disease
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 362
- Registration Number
- NCT02249403
Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)
Phase 1
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Drug: High dose of BIIL 284 BS tabletsDrug: Low dose of BIIL 284 BS tabletsDrug: Placebo
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 26
- Registration Number
- NCT02247375
Comparison of the Effect of Tipranavir and Ritonavir or Tipranavir and Ritonavir on the Pharmacokinetic Characteristics of Zidovudine in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT02249416
Study to Determine the Pharmacokinetics on TPV/r in Subjects With Mild and Moderate Hepatic Insufficiency
Phase 1
Completed
- Conditions
- Hepatic Insufficiency
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02249442
Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir
Phase 2
Completed
- Conditions
- HIV Infections
- Interventions
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT02249130
Post Marketing Surveillance And Special Surveillance for Mirapex® Tablet in Patients With Idiopathic Parkinson's Disease
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1449
- Registration Number
- NCT02248168
The Effect of BIIL 284 BS on Induced-sputum Variables in Patients With Bronchial Asthma
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2014-09-26
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 38
- Registration Number
- NCT02249312